Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.

Muhammad Wasif Saif

Journal: Expert opinion on biological therapy 2014;13(11):1489-93

PMID: 24050123

Abstract

Recent updates in the second-line treatment of patients with metastatic colorectal cancer (mCRC) have indicated the benefit of adding aflibercept (plus FOLFIRI) after an oxaliplatin-containing regimen (with or without bevacizumab) or a bevacizumab-containing regimen after progression on a different bevacizumab-containing regimen. This has led some oncologists to compare the trials and equate the drugs, with the assumption that they confer equal efficacy, but the background of this must be adequately assessed before reaching this conclusion. In fact, the publication of these trial results has left oncologists with much to consider for their mCRC patients who will eventually progress on a first-line chemotherapy/bevacizumab regimen. The author comments on this issue and emphasizes the need for additional research into antiangiogenic biomarkers to identify patients who are likely to respond to one drug more than another.

Address: Experimental Therapeutics Program, Tufts University School of Medicine , 800 Washington Street, Suite 7S-7099, Boston, MA 02111 , USA +1 617 636 8077 ; +1 617 636 7060 ; [email protected].

DOI: 10.1517/14712598.2013.837881

Link outs

Free resources

Medical:

https://medlineplus.gov/colorectalcancer.html

Other Literature Sources:

https://scite.ai/reports/24050123

Subscription / membership required

Full Text Sources:

https://www.tandfonline.com/doi/10.1517/14712598.2...

MeSH Terms: Adenocarcinoma, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Colorectal Neoplasms, Disease-Free Survival, Double-Blind Method, Fluorouracil, Humans, Leucovorin, Multicenter Studies as Topic, Neoplasm Proteins, Organoplatinum Compounds, Oxaliplatin, Patient Selection, Placenta Growth Factor, Pregnancy Proteins, Prospective Studies, Randomized Controlled Trials as Topic, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Salvage Therapy, Treatment Outcome, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor B, Vascular Endothelial Growth Factor Receptor-1, Vascular Endothelial Growth Factor Receptor-2